Although some studies have reported that systemic knockdown of TLR4 reduces inflammation in AP models,16,17 others have found that this is not significant.7,8 Despite the controversy, TLR4 has been regarded as a potentially promising therapeutic target in AP.6 However, previous studies mainly focused on the effects of systemic TLR4 knockout during AP, while the role of intestinal TLR4 in AP and AP-associated gut injury remains unclear. The gene discussed is TLR4; the disease is alkaline phosphatase measurement.